Skip to main content

Compare Stocks

Date Range: 

 Fennec PharmaceuticalsVincerx PharmaResverlogixIMVBioventix
SymbolTSE:FRXNASDAQ:VINCTSE:RVXTSE:IMVLON:BVXP
Price Information
Current PriceC$7.66$16.86C$0.87C$2.81GBX 4,160
52 Week RangeBuyBuyN/AHoldN/A
MarketRank™
Overall Score0.51.00.71.20.8
Analysis Score0.00.00.03.00.0
Community Score2.65.03.62.81.8
Dividend Score0.00.00.00.01.7
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.00.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyN/AHoldN/A
Consensus Price TargetN/A$33.00N/AC$4.03N/A
% Upside from Price TargetN/A95.73% upsideN/A43.53% upsideN/A
Trade Information
Market CapC$199.18 million$235.77 millionC$207.73 millionC$190.27 million£216.69 million
BetaN/AN/AN/AN/AN/A
Average Volume1,39491,12458,802142,0125,774
Sales & Book Value
Annual RevenueC$170,000.00N/AN/AC$3,000.00£10.38 million
Price / Sales1,171.66N/AN/A63,422.6420.88
CashflowC$1.22 per shareN/AC$0.00 per shareC$0.59 per shareGBX 112.82 per share
Price / Cash6.26N/A800.004.7436.87
Book ValueC$1.12 per shareN/AC($0.17) per shareC$0.59 per shareGBX 197.90 per share
Price / Book6.85N/AN/A4.790.21
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSC($0.93)N/AC$0.01C($0.58)GBX 131.20
Trailing P/E RatioN/A0.0062.14N/A31.71
Forward P/E Ratio
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AGBX 0.88
Dividend YieldN/AN/AN/AN/A0.02%
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/A0.67%
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A25.87%N/A
Current Ratio13.39%N/A0.17%5.34%11.69%
Quick Ratio12.93%N/A0.08%4.80%11.42%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees928257712
Shares Outstanding26.00 million13.98 million238.77 million67.71 million5.21 million
Next Earnings Date8/4/2021 (Estimated)N/A9/10/2021 (Estimated)8/11/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Heres What Bioventix PLCs (LON:BVXP) Shareholder Ownership Structure Looks LikeHere's What Bioventix PLC's (LON:BVXP) Shareholder Ownership Structure Looks Like
finance.yahoo.com - March 29 at 8:26 AM
Bioventix PLC Stock Is Believed To Be Fairly ValuedBioventix PLC Stock Is Believed To Be Fairly Valued
gurufocus.com - March 28 at 11:49 AM
Bioventix PLCs (LON:BVXP) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?Bioventix PLC's (LON:BVXP) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
finance.yahoo.com - February 21 at 7:54 AM
If You Like EPS Growth Then Check Out Bioventix (LON:BVXP) Before Its Too LateIf You Like EPS Growth Then Check Out Bioventix (LON:BVXP) Before It's Too Late
finance.yahoo.com - January 22 at 9:27 AM
Did You Participate In Any Of Bioventixs (LON:BVXP) Incredible 312% Return?Did You Participate In Any Of Bioventix's (LON:BVXP) Incredible 312% Return?
finance.yahoo.com - December 23 at 8:50 AM
Why Bioventixs (LON:BVXP) CEO Pay MattersWhy Bioventix's (LON:BVXP) CEO Pay Matters
finance.yahoo.com - November 23 at 2:23 PM
Four Days Left To Buy Bioventix PLC (LON:BVXP) Before The Ex-Dividend DateFour Days Left To Buy Bioventix PLC (LON:BVXP) Before The Ex-Dividend Date
finance.yahoo.com - October 24 at 9:26 AM
What Type Of Shareholders Own The Most Number of Bioventix PLC (LON:BVXP) Shares?What Type Of Shareholders Own The Most Number of Bioventix PLC (LON:BVXP) Shares?
uk.news.yahoo.com - September 28 at 7:10 AM
Could The Market Be Wrong About Bioventix PLC (LON:BVXP) Given Its Attractive Financial Prospects?Could The Market Be Wrong About Bioventix PLC (LON:BVXP) Given Its Attractive Financial Prospects?
finance.yahoo.com - August 23 at 9:00 AM
Factors that could predict the future for shares in BioventixFactors that could predict the future for shares in Bioventix
uk.finance.yahoo.com - August 19 at 8:16 AM
Four signs of a competitive moat at Bioventix (LON:BVXP)Four signs of a competitive moat at Bioventix (LON:BVXP)
uk.finance.yahoo.com - August 4 at 9:24 AM
With EPS Growth And More, Bioventix (LON:BVXP) Is InterestingWith EPS Growth And More, Bioventix (LON:BVXP) Is Interesting
finance.yahoo.com - July 16 at 8:51 AM
Why Bioventix (LON:BVXP) will appeal to moat investorsWhy Bioventix (LON:BVXP) will appeal to moat investors
uk.finance.yahoo.com - July 3 at 9:41 AM
Bioventix Plc - Appointment of CFOBioventix Plc - Appointment of CFO
www.finanznachrichten.de - July 1 at 9:13 AM
Can Bioventix resist market uncertainty?Can Bioventix resist market uncertainty?
uk.finance.yahoo.com - June 18 at 9:29 AM
Navigating healthcare in 7 stepsNavigating healthcare in 7 steps
www.investorschronicle.co.uk - June 3 at 10:55 AM
Bioventix (LON:BVXP) price about to hit new 52-week highBioventix (LON:BVXP) price about to hit new 52-week high
uk.finance.yahoo.com - May 19 at 12:39 PM
Is Bioventix PLCs (LON:BVXP) CEO Paid At A Competitive Rate?Is Bioventix PLC's (LON:BVXP) CEO Paid At A Competitive Rate?
finance.yahoo.com - May 17 at 8:02 AM
Is Bioventix PLC's (LON:BVXP) CEO Paid At A Competitive Rate?Is Bioventix PLC's (LON:BVXP) CEO Paid At A Competitive Rate?
finance.yahoo.com - May 17 at 8:02 AM
Disentangling the effect of Covid-19 on Bioventixs share priceDisentangling the effect of Covid-19 on Bioventix's share price
uk.finance.yahoo.com - April 27 at 9:44 AM
What Is Bioventixs (LON:BVXP) P/E Ratio After Its Share Price Rocketed?What Is Bioventix's (LON:BVXP) P/E Ratio After Its Share Price Rocketed?
finance.yahoo.com - April 17 at 11:03 AM
What Is Bioventix's (LON:BVXP) P/E Ratio After Its Share Price Rocketed?What Is Bioventix's (LON:BVXP) P/E Ratio After Its Share Price Rocketed?
finance.yahoo.com - April 17 at 11:03 AM
Interested In Bioventix PLC (LON:BVXP)’s Upcoming 1.0% Dividend? You Have 3 Days LeftInterested In Bioventix PLC (LON:BVXP)’s Upcoming 1.0% Dividend? You Have 3 Days Left
finance.yahoo.com - April 5 at 6:45 AM
Bioventix Plc - Director/PDMR ShareholdingBioventix Plc - Director/PDMR Shareholding
uk.finance.yahoo.com - April 2 at 8:40 PM
Bioventix Plc - Correction: Interim ResultsBioventix Plc - Correction: Interim Results
www.finanznachrichten.de - March 31 at 3:30 PM
DateCompanyBrokerageAction
3/17/2021Fennec PharmaceuticalsWedbushReiterated Rating
6/5/2020Fennec PharmaceuticalsCantor FitzgeraldReiterated Rating
10/10/2018Fennec PharmaceuticalsDawson JamesReiterated Rating
1/6/2021Vincerx PharmaChardan CapitalInitiated Coverage
5/23/2019ResverlogixRoth CapitalReiterated Rating
5/13/2021IMVRaymond JamesReiterated Rating
5/13/2021IMVNational Bank FinancialLower Price Target
5/13/2021IMVNational BanksharesLower Price Target
3/18/2021IMVLeede Jones GabReiterated Rating
3/31/2020IMVB. RileyDowngrade
11/26/2019IMVOppenheimerSet Price Target
3/25/2019IMVHC WainwrightReiterated Rating
12/13/2018IMVEchelon Wealth PartnersReiterated Rating
6/5/2018IMVMackieBoost Price Target
3/30/2020BioventixFinnCapReiterated Rating
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.